Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
megestrol acetate + serplulimab + S-1 + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination therapy is being evaluated in a Phase II clinical trial for the treatment of cancer-associated cachexia in patients with locally advanced (cStage III) gastric or gastroesophageal junction (GEJ) adenocarcinoma. The regimen integrates megestrol acetate, a synthetic progestin used as an appetite stimulant, with a neoadjuvant chemo-immunotherapy backbone consisting of serplulimab (an anti-PD-1 monoclonal antibody) and the SOX regimen (S-1 and oxaliplatin). The study, led by The First Affiliated Hospital with Nanjing Medical University, investigates whether adding megestrol acetate oral suspension to the standard neoadjuvant treatment improves nutritional status, mitigates weight loss, and enhances the efficacy of neoadjuvant therapy, potentially leading to improved surgical outcomes and radical D2 resection rates.
- Brand names
- HANSZHUO
- Other names
- megestrol acetate + serplulimab + SOX
02
Targets
TS (Thymidylate synthase)PR (Progesterone receptor)DNAPDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on megestrol acetate + serplulimab + S-1 + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on megestrol acetate + serplulimab + S-1 + oxaliplatin.